HLA-G and plasma cell myeloma: The study conducted by Bataille, Durie, and Grenierj in 2017 evaluated and correlated B2microglobulin with clinical data and the response to chemotherapy of patients with myeloma and demonstrated an increase in the survival rate in patients with a low level of B2microglobulin by up to 52 months compared to an increased level of B2microglobulin, which conferred a much lower survival rate of 26 months.